Matteo S. Carlino - Concepedia

Author

Matteo S. Carlino

Also Known As

Carlino, Matteo S, David E Fisher, M Carlino, M S Carlino, M. Carlino, M. S. Carlino, M.S. Carlino, Marina Carlino, Matteo Carlino, Matteo S Carlino

661

Publications

56.2K

Citations

H-Index

Concepts

All Affiliations

Melanoma Institute Australia The University of Sydney Royal North Shore Hospital Blacktown & Mount Druitt Hospital Westmead Hospital

About

Matteo S. Carlino is an author at Melanoma Institute Australia specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	99	13.4K
2	Health Sciences	19	25	3.5K
3	Engineering	2	2	292
4	Allergy	1	1	121
5	Biostatistics	1	1	17

Matteo S. Carlino

217

Publications

50.9K

Citations

H-Index

Page 1

	Year	Citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert, Jacob Schachter, Georgina V. Long, New England Journal of Medicine	2015	5.7K
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2017	5.3K
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2019	3.6K
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, New England Journal of Medicine	2018	1.8K
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas, Igor Puzanov, Reinhard Dummer, The Lancet Oncology MedicineMelanomaImmunologyClinical TrialsImmune Checkpoint Inhibitor	2015	1.5K
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Jacob Schachter, Antoni Ribas, Georgina V. Long, The Lancet Open-label Phase 3MedicineMelanomaImmune Checkpoint InhibitorDermatology	2017	1.2K
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy Jarushka Naidoo, Xuan Wang, Kaitlin M. Woo, Journal of Clinical Oncology	2016	1.1K
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Caroline Robert, Antoni Ribas, Jacob Schachter, The Lancet Oncology MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2019	1.1K
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy Tuba N. Gide, Camelia Quek, Alexander M. Menzies, Cancer Cell	2019	980

Page 1